Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 3/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466236 | 0.89 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL24632922 | 0.89 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL30088637 | 0.89 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL22872157 | 0.89 | NPC1L1 (0.57) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL29819604 | 0.85 | NPC1L1 (0.62) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL131383 | 0.82 | NPC1L1 (0.70) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL1937432 | 0.82 | CYP2D6 (0.60) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL13988168 | 0.82 | NPC1L1 (0.70) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL14007452 | 0.82 | NPC1L1 (0.70) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL15107562 | 0.82 | NPC1L1 (0.70) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7641914-B2 | for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs | GENCELL, S.A. (FR) | 2010-01-05 | — | — | US | claimed |
| EP-0984925-B1 | COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | claimed |
| EP-0986568-B1 | NOVEL CLASS OF NUCLEIC ACID CATIONIC TRANSFECTING AGENTS | AVENTIS PHARMA SA (FR) | 2002-03-20 | — | — | EP | claimed |
| US-6300321-B1 | LIPOPOLYAMINES | AVENTIS PHARMA S.A. (FR) | 2001-10-09 | — | — | US | claimed |
| US-7641914-B2 | for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs | GENCELL, S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20050222434-A1 | Acid-sensitive compounds, their preparation and uses | GENCELL S.A. | 2005-10-06 | — | — | US | disclosed |
| US-6812218-B2 | TRANSFERRING NUCLEIC ACIDS TO CELLS | GENCELL S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-20030065033-A1 | Lipid derivatives of polythiourea | GENCELL S.A. (FR) | 2003-04-03 | — | — | US | disclosed |
| US-20020091242-A1 | Acid-sensitive compounds, their preparation and uses | GENCELL S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6300321-B1 | LIPOPOLYAMINES | AVENTIS PHARMA S.A. (FR) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222434-A1 | Acid-sensitive compounds, their preparation and uses | LIPA, PHOSPHO1, ACP1 | NPC1L1 76/4885USP2 954/4885LMNA 2003/4885 |
| US-20030065033-A1 | Lipid derivatives of polythiourea | ABCB4, TENT4A, PEBP1 | NPC1L1 64/4885USP2 3014/4885LMNA 437/4885 |
| US-20020091242-A1 | Acid-sensitive compounds, their preparation and uses | LIPA, PHOSPHO1, ACP1 | NPC1L1 76/4885USP2 954/4885LMNA 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.